NCT00344786 - Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

July 31, 2008

Study Completion Date

September 30, 2008

Conditions

B-Cell Chronic Lymphocytic Leukemia

Interventions

DRUG

CNF2024 (BIIB021)

"Dose starting at 12.5 mg/d, p.o. as a once-daily dose for 21 days followed by a 1-week rest period.~Dose escalation will proceed according to the predetermined scheme until the maximum tolerated dose (MTD) is reached due to dose limiting toxicities (DLT) during the first course of treatment."

Trial Locations (3)

10021

Research site, New York

77030

Research site, Houston

92093

Research Site, San Diego